List of Excipients in Branded Drug INVOKANA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	INVOKANA	canagliflozin	50090-4364	ANHYDROUS LACTOSE
A-S Medication Solutions	INVOKANA	canagliflozin	50090-4364	CELLULOSE, MICROCRYSTALLINE
A-S Medication Solutions	INVOKANA	canagliflozin	50090-4364	CROSCARMELLOSE SODIUM

INVOKANA Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Invokana (canagliflozin) is an immediate-release, film-coated tablet with a relatively conventional excipient system. Its main commercial opportunities are generic supply, excipient substitution, coating optimization, combination-product manufacturing, and regional lifecycle products. The largest technical constraints are dose uniformity, dissolution, moisture control, tablet robustness, and the need to demonstrate pharmaceutical equivalence under the FDA ANDA pathway.

What is Invokana and how is it regulated?

Invokana contains canagliflozin, a sodium-glucose cotransporter 2 inhibitor used for type 2 diabetes and certain cardiovascular and renal-risk populations. Janssen Pharmaceuticals received FDA approval for Invokana tablets in March 2013 under NDA 204042.[1]

Attribute	Invokana
Active ingredient	Canagliflozin
Drug class	SGLT2 inhibitor
Dosage form	Immediate-release, film-coated tablet
Strengths	100 mg and 300 mg
FDA approval	March 29, 2013
NDA	204042
Innovator	Janssen Pharmaceuticals, Inc.
Therapeutic category	Type 2 diabetes; cardiovascular and renal risk reduction
Generic pathway	ANDA, not biosimilar
Orange Book status	Drug-specific patent and exclusivity records apply

Invokana is a small-molecule drug. Biosimilar competition is therefore irrelevant. The competitive pathway is generic substitution through ANDAs, subject to pharmaceutical equivalence, bioequivalence, manufacturing controls, and any remaining listed-patent obligations.

What excipients are used in Invokana tablets?

The Invokana tablet core uses standard direct-compression or high-shear tableting excipients. Public product information identifies the principal inactive ingredients as microcrystalline cellulose, lactose anhydrous, croscarmellose sodium, magnesium stearate, and hypromellose. The film coat contains conventional coating materials, including polyvinyl alcohol, macrogol or polyethylene glycol, talc, titanium dioxide, and strength-specific colorants.[2]

Formulation function	Invokana excipient category	Commercial purpose
Diluent and compression aid	Microcrystalline cellulose	Tablet mass, compactability, mechanical strength
Diluent	Anhydrous lactose	Bulk, flow, compression, cost control
Disintegrant	Croscarmellose sodium	Rapid tablet breakup and dissolution
Lubricant	Magnesium stearate	Ejection from tooling and prevention of sticking
Film former	Polyvinyl alcohol or hypromellose-type polymer	Surface protection and appearance
Plasticizer or coating modifier	Macrogol/polyethylene glycol	Flexibility and coating performance
Opacifier	Titanium dioxide	Appearance and light protection
Anti-tacking agent	Talc	Coating process control
Colorant	Iron oxide or other approved colorant	Strength identification

The exact composition can vary by market, manufacturing site, and regulatory presentation. The US product label and the FDA Inactive Ingredient Database are the controlling references for US formulation and excipient precedent.[2,3]

Why does the excipient profile matter?

Canagliflozin has a low-dose-to-moderate-dose tablet presentation, with 100 mg and 300 mg strengths. The formulation must deliver consistent drug distribution despite the relatively small active mass compared with the complete tablet. Excipient selection therefore affects:

• content uniformity;
• powder flow;
• tablet tensile strength;
• friability;
• disintegration;
• dissolution across pH conditions;
• sensitivity to lubricant concentration;
• coating adhesion;
• packaging stability; and
• manufacturing throughput.

Anhydrous lactose and microcrystalline cellulose provide a cost-efficient base. Croscarmellose sodium supports rapid disintegration without requiring a complex modified-release system. Magnesium stearate remains commercially attractive because it is inexpensive and widely available, but excessive lubrication can slow wetting and dissolution.

What excipient strategy is most suitable for Invokana generics?

The strongest generic strategy is a low-risk formulation that retains the functional architecture of the reference product while optimizing manufacturability and supply resilience.

Direct-compression strategy

A direct-compression blend can reduce processing steps, solvent use, drying time, and equipment requirements. The principal development risks are:

• poor flow from micronized or poorly flowing canagliflozin;
• segregation between the active and excipient fractions;
• insufficient tablet hardness at commercial press speeds;
• over-lubrication;
• variable dissolution after scale-up; and
• sensitivity to ambient humidity.

A co-processed filler combining microcrystalline cellulose with another compressible component may improve flow and tablet robustness. The formulation must remain compatible with the reference product’s dissolution profile and the ANDA’s inactive-ingredient requirements.

Dry granulation

Roller compaction can improve blend uniformity and reduce segregation where direct compression is inadequate. It is attractive for high-volume generic manufacturing because it avoids aqueous or organic granulation solvents. The main risks are excessive granule densification, slower disintegration, and changes in dissolution after milling.

Wet granulation

Wet granulation may improve content uniformity and compactability but adds drying and residual-moisture controls. It is less attractive when the active or formulation is moisture-sensitive. It also increases process validation requirements and can create additional dissolution variability.

Film-coating strategy

The film coat has limited therapeutic value but has commercial importance. It supports:

• tablet identification by strength;
• protection against abrasion;
• improved swallowability;
• visual differentiation;
• branding or private-label presentation; and
• control of moisture and light exposure.

A generic manufacturer can evaluate lower-cost coating systems, reduced coating weight gain, and regional colorant substitutions. Any change must preserve appearance, stability, product identification, and regulatory acceptability.

What formulation patents protect Invokana?

Invokana’s primary intellectual-property position is based on canagliflozin compound, crystalline-form, formulation, and therapeutic-use patents. The relevant patent estate has included Janssen and related Johnson & Johnson entities, with rights originating from development work associated with Mitsubishi Tanabe Pharma.[4,5]

Patent category	Relevance to Invokana	Generic impact
Canagliflozin compound patents	Protect the active pharmaceutical ingredient	Potential composition-of-matter barrier
Crystalline-form patents	Protect solid-state forms and physical properties	May constrain API sourcing or solid-form selection
Pharmaceutical-composition patents	Cover tablets or compositions containing canagliflozin	May affect formulation design
Method-of-use patents	Cover diabetes, cardiovascular, renal, or related uses	Relevant to labeling and induced-infringement risk
Manufacturing patents	Cover processes or intermediates	May require an alternative API route
Combination-product patents	Cover canagliflozin with metformin or other agents	Relevant to Invokamet and Invokamet XR, not necessarily standalone Invokana

Publicly associated US patents include US 7,884,849 and US 8,513,202, although the operative scope and expiration dates depend on patent-term adjustment, terminal disclaimers, PTA calculations, and Orange Book listing status.[6,7] Patent numbers alone do not establish whether a generic applicant can launch. The controlling analysis requires the current Orange Book, the listed claims, any Paragraph IV notice, and the status of related district-court or appellate proceedings.[8]

When does Invokana lose exclusivity?

Invokana’s statutory exclusivity has expired. The commercial question is patent-controlled generic entry.

The principal timeline is:

Event	Date or status
FDA approval of Invokana	March 29, 2013
New chemical entity exclusivity	Expired
Five-year NCE period	Expired in 2018
Three-year exclusivity for later clinical changes	Applicable periods have expired
Core compound patent position	Subject to listed patent and PTA analysis
Crystalline-form and related patents	Some protections may extend beyond the core compound term
Generic entry	Depends on ANDA approval, Paragraph IV outcomes, settlements, and non-patent barriers

The core small-molecule exclusivity period is no longer the principal barrier. A generic applicant may file an ANDA with Paragraph IV certifications against unexpired listed patents. A successful Paragraph IV challenge can create a 180-day shared exclusivity period for the first qualifying applicant. A Paragraph III certification can delay approval until the relevant patent expiration.

What is the Orange Book status of Invokana?

The FDA Orange Book identifies approved drug products, therapeutic equivalence evaluations, patent information, and exclusivity records. For Invokana, the Orange Book is the primary source for determining:

• whether a patent is listed against NDA 204042;
• the expiration date recorded by FDA;
• whether a patent covers the drug substance, product, or method of use;
• whether a first applicant may qualify for 180-day exclusivity; and
• whether an ANDA applicant must make a Paragraph IV certification.[8]

Orange Book entries do not automatically determine infringement. They define the patent-certification framework used in the ANDA process. A generic manufacturer still needs a claim-by-claim freedom-to-operate assessment covering API, solid form, formulation, labeling, and manufacturing process.

Which companies are challenging Invokana patents?

Invokana has been subject to generic competition and patent challenges in the US generic-drug market. The relevant challengers can change as ANDAs are transferred, withdrawn, settled, or approved. Patent litigation searches should cover:

• Janssen Pharmaceuticals, Inc. and related Johnson & Johnson entities;
• ANDA applicants filing Paragraph IV certifications;
• district-court cases under the Hatch-Waxman framework;
• Federal Circuit appeals;
• consent judgments;
• confidential or public settlement terms; and
• FDA approval and launch status for each ANDA.

A current challenge list cannot be inferred from historical litigation alone. The FDA Orange Book, PACER records, FDA approval letters, and company filings must be reconciled before assigning a launch date or litigation risk.[8-10]

What patent litigation and settlement issues affect generic launch?

The main litigation issues are likely to fall into five categories.

Composition-of-matter claims

These claims create the strongest barrier if they remain unexpired and valid. A successful invalidity or non-infringement position can materially accelerate launch.

Crystalline-form claims

Solid-form patents can be commercially significant even after the basic compound patent expires. An API supplier may need to produce a different polymorph, hydrate, solvate, or amorphous form, provided the form is suitable for the ANDA and does not infringe valid claims.

Method-of-use claims

FDA-approved indications can create labeling constraints. A generic applicant may use a section viii statement to carve out patented indications where legally available. The resulting label must avoid inducing use for the carved-out indication.

Formulation claims

A formulation patent may cover excipient ratios, tablet composition, dissolution properties, or specific dosage forms. A non-infringing formulation can preserve generic entry if it meets bioequivalence and quality requirements.

Settlement agreements

Settlements may provide an agreed launch date before the latest patent expiration. They can also impose restrictions on authorized generic arrangements, product supply, or launch conditions. The economic value of a settlement depends on the negotiated entry date, the number of approved applicants, and the probability that the relevant patents survive challenge.

What commercial opportunities exist in Invokana excipients?

Generic excipient supply

The most immediate opportunity is supply of high-volume, compendial materials:

• microcrystalline cellulose;
• anhydrous lactose;
• croscarmellose sodium;
• magnesium stearate;
• polyvinyl alcohol;
• polyethylene glycol or macrogol;
• talc; and
• titanium dioxide.

Suppliers with dual compendial compliance, low extractables, strong lot-to-lot consistency, and regional manufacturing capacity can compete for ANDA and contract-manufacturing programs.

Co-processed excipients

Co-processed fillers and disintegrant systems may improve flow, compressibility, and production speed. The opportunity is strongest where a generic manufacturer has difficulty matching dissolution using standard single-component excipients.

The supplier must support:

• compendial specifications;
• regulatory documentation;
• elemental-impurity controls;
• nitrosamine risk assessment where relevant;
• microbial limits;
• residual-solvent data;
• stability data; and
• change-notification commitments.

Coating systems

Preformulated film-coating systems can reduce development time and simplify color matching between strengths. Suppliers can differentiate through low coating weight, faster processing, lower dust generation, and improved resistance to chipping.

Supply-chain substitution

A second-source strategy has commercial value because generic manufacturers may need to replace an excipient affected by:

• regional shortages;
• plant shutdowns;
• freight disruption;
• quality investigations;
• changes in compendial monographs;
• geopolitical restrictions; or
• supplier concentration.

The replacement must be supported through comparability, process validation, stability, and regulatory change control.

Excipient-enabled lifecycle products

Opportunities are more limited for standalone Invokana because the reference product is immediate release. The strongest lifecycle opportunities are associated with:

• canagliflozin-metformin combinations;
• fixed-dose products;
• alternative tablet sizes;
• improved swallowability;
• lower-cost coating systems;
• regional packaging configurations; and
• products designed for markets where the original combination product is unavailable.

Modified-release or novel-delivery products would require a more substantial clinical and regulatory program and would not be a simple excipient substitution.

How does Invokana compare with other SGLT2 inhibitors?

Product	Active ingredient	Original sponsor	Dosage-form opportunity	Patent and competition profile
Invokana	Canagliflozin	Janssen	Immediate-release tablet; combination products	Generic and formulation competition
Farxiga/Forxiga	Dapagliflozin	AstraZeneca	Immediate-release tablet; combination products	Separate patent estate and launch timing
Jardiance	Empagliflozin	Boehringer Ingelheim/Eli Lilly	Immediate-release tablet; combination products	Separate patent estate and generic timing
Steglatro	Ertugliflozin	Merck/Pfizer	Immediate-release tablet; combination products	Smaller commercial base and separate IP

The excipient opportunity is not determined only by tablet composition. It also depends on prescription volume, number of approved ANDAs, API availability, patent settlement dates, and payer substitution. Invokana’s early approval date creates a mature generic opportunity, but competing SGLT2 products may offer larger commercial volumes or later patent cliffs.

What FDA regulatory risks apply to an Invokana generic?

An ANDA applicant must establish pharmaceutical equivalence and bioequivalence to the reference listed drug. Relevant controls include:

1. identical active ingredient, strength, dosage form, and route of administration;
2. acceptable inactive ingredients for the route and population;
3. dissolution similarity;
4. content uniformity;
5. stability through the proposed shelf life;
6. tablet hardness and friability;
7. impurity and degradation-product control;
8. manufacturing-process validation;
9. container-closure protection; and
10. labeling that complies with any applicable method-of-use patent carve-outs.

Excipient changes can trigger regulatory consequences even when the active ingredient is unchanged. A change in disintegrant grade, lubricant level, lactose type, coating system, or tablet density can alter dissolution or bioequivalence performance.

How strong is the Invokana patent estate?

The estate is strongest where it covers the active compound or a commercially necessary solid form. Formulation and method-of-use patents are more vulnerable to design-around strategies, but they can still delay approval or restrict labeling.

IP layer	Relative commercial strength	Design-around potential
Active compound	High while unexpired	Low
Required crystalline form	Medium to high	Medium
Tablet formulation	Medium	Medium to high
Method of use	Medium	Depends on indication and labeling
Manufacturing process	Variable	Often higher
Combination product	Product-specific	Depends on formulation and claim scope

The commercial risk is therefore bifurcated. API and solid-form freedom to operate determine whether a generic can manufacture the product. Excipient and formulation design determine whether the finished dosage form can reach bioequivalence without infringing remaining claims.

What revenue exposure and launch scenarios matter?

Invokana’s revenue exposure has declined from its early commercial period as SGLT2 competition expanded and prescribing shifted toward broader cardiovascular and renal outcome positioning across the class. Johnson & Johnson reports Invokana sales in its annual filings, while product-level revenue should be analyzed against the company’s total Innovative Medicine portfolio and the performance of Jardiance and Farxiga.[9]

Three launch scenarios are commercially relevant:

Scenario	Timing	Market effect
Early launch after patent settlement	Before all listed patents expire	Rapid price erosion and share capture
Launch after litigation victory or patent expiry	At or near the final enforceable patent date	Multiple generic entrants likely
Delayed launch from formulation or approval issues	After expected entry date	Innovator retains share longer; first-mover value declines

For excipient suppliers, the best opportunity generally occurs before ANDA approval, when formulation developers qualify materials and lock commercial sources. After multiple generics launch, price competition shifts value toward reliable supply, lower total manufacturing cost, and reduced deviation rates.

Key Takeaways

• Invokana is a canagliflozin immediate-release tablet available in 100 mg and 300 mg strengths.
• Its core excipient system uses conventional diluents, disintegrants, lubricants, and film-coating materials.
• The strongest generic strategy is a robust direct-compression or dry-granulation process with tight control of blend uniformity and dissolution.
• The main commercial excipient opportunities are microcrystalline cellulose, anhydrous lactose, croscarmellose sodium, magnesium stearate, and preformulated coating systems.
• Invokana is subject to generic, not biosimilar, competition.
• Patent analysis must distinguish compound, crystalline-form, formulation, method-of-use, and manufacturing claims.
• Orange Book listings and current Hatch-Waxman litigation determine practical launch risk.
• Excipient substitution can create regulatory risk if it changes dissolution, content uniformity, stability, or bioequivalence.
• Combination products such as canagliflozin-metformin create separate formulation and patent opportunities.

FAQs

Can a generic Invokana use different excipients?

Yes. An ANDA may use different inactive ingredients if they are acceptable for the dosage form and the product meets pharmaceutical-equivalence, bioequivalence, quality, and labeling requirements.

Is lactose-free Invokana commercially feasible?

A lactose-free formulation may be feasible, but it would require replacement of the lactose diluent with a suitable alternative and demonstration that tablet performance, dissolution, stability, and bioequivalence remain acceptable.

Are Invokana excipients protected by patents?

Individual common excipients generally are not the principal patent barrier. Risk may arise from patents claiming a specific pharmaceutical composition, excipient ratio, tablet structure, dissolution profile, or manufacturing process.

Does Invokana require a biosimilar approval?

No. Canagliflozin is a small molecule. Follow-on products use the ANDA generic-drug pathway rather than the biosimilar pathway.

What is the highest-value excipient opportunity for an Invokana generic?

The strongest opportunity is usually a reliable, cost-competitive combination of compressible diluent and disintegrant supported by coating-system supply. The commercial advantage comes from manufacturing consistency, dissolution control, and uninterrupted supply rather than from a novel excipient claim.

References

1. U.S. Food and Drug Administration. (2013). Invokana (canagliflozin) prescribing information, NDA 204042.
2. Janssen Pharmaceuticals, Inc. (2023). Invokana (canagliflozin) tablets: Full prescribing information.
3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.
4. Mitsubishi Tanabe Pharma Corporation. (2014). Annual report.
5. Johnson & Johnson. (2023). Annual report.
6. U.S. Patent No. 7,884,849. (2011). C-glucoside derivatives.
7. U.S. Patent No. 8,513,202. (2013). Crystalline forms of C-glucoside compounds.
8. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
9. Johnson & Johnson. (2023). Form 10-K and Innovative Medicine product sales disclosures.
10. U.S. Courts. (n.d.). Public federal case records for Hatch-Waxman patent litigation.